Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT1019 Combined With SBRT and PD-1 Inhibitor for Advanced Solid Tumors
NCT07285395Phase 1Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AT1019 in solid tumor (advanced stage), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Dose-limiting toxicity at 4 weeks, Maximum tolerated dose at 4 weeks and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
AT1019
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07285395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285395.